CLRB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CLRB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cellectar Biosciences's change in inventory for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Cellectar Biosciences's inventory stayed the same from Sep. 2023 to Dec. 2023 .
Cellectar Biosciences's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Cellectar Biosciences's inventory stayed the same from Dec. 2022 to Dec. 2023 .
Cellectar Biosciences's Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Cellectar Biosciences's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellectar Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Cellectar Biosciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellectar Biosciences (NAS:CLRB) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Cellectar Biosciences's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= | N/A |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Cellectar Biosciences's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0 | / | 0 | |
= | N/A |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Cellectar Biosciences's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Cellectar Biosciences's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrei Shustov | officer: Senior Vice President, Medical | 7 PARKLAND DRIVE, MILFORD NJ 08848 |
Darrell Shane Lea | officer: Chief Commercial Officer | 7 PARKLAND DRIVE, MILFORD NJ 08848 |
Chad J Kolean | officer: Chief Financial Officer | C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE, MADISON WI 53716 |
Douglas J Swirsky | director | C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850 |
Frederick W Driscoll | director | |
Asher Chanan-khan | director | C/O CELLECTAR BISCIENCES, INC., 100 CAMPUS DRIVE NJ 07932 |
James V Caruso | director, officer: President and CEO | C/O CELLECTAR BIOSCIENCES, INC., 8383 GREENWAY BLVD STE 600, MIDDLETON WI 53562 |
Dov Elefant | officer: Chief Financial Officer | EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632 |
Jarrod Longcor | officer: Chief Business Officer | C/O RIB-X PHARMACEUTICALS, INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511 |
Friend John E. Ii | officer: VP, Chief Medical Officer | 26 ORCHARD LANE, COLT NECK NJ 07722 |
John Neis | director | 505 S. ROSA ROAD, SUITE 201, MADISON WI 53719 |
Stefan Loren | director | 3226 AVENIDA DE SUENO, CARLSBAD CA 92009 |
Stephen A Hill | director | 50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999 |
Igor D Grachev | officer: Chief Medical Officer | 15 REID LANE, MILLSTONE TWP NJ 08535 |
Bernhardt Charles Thomas Iii | officer: Interim CFO | 23 BIRCH ROAD, MALVERN PA 19355 |
From GuruFocus
By Marketwired • 10-24-2023
By Value_Insider Value_Insider • 10-21-2022
By Value_Insider Value_Insider • 11-16-2022
By GuruFocusNews GuruFocusNews • 05-20-2022
By Marketwired • 06-28-2023
By sperokesalga sperokesalga • 02-15-2023
By Value_Insider Value_Insider • 11-03-2022
By GuruFocusNews GuruFocusNews • 06-09-2022
By Marketwired • 09-05-2023
By GuruFocusNews GuruFocusNews • 07-09-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.